GRB2 Promotes Sorafenib Resistance in Hepatocellular Carcinoma Cells Under Hypoxia by Activating the PI3K/AKT Signaling Pathway

Jiaqian He, Yinzhi Kong, Yunyong Wang, Qiaoling Fang, Hemeng Wu, Kewei Du, Yuzhen Luo, Jinna Tan, Hui Yin, Hongsheng Lin, Mingfen Li · 2026

Read GRB2 Promotes Sorafenib Resistance in Hepatocellular Carcinoma Cells Under Hypoxia by Activating the PI3K/AKT Signaling Pathway by Jiaqian He, Yinzhi Kong, Yunyong Wang, Qiaoling Fang, Hemeng Wu, Kewei Du, Yuzhen Luo, Jinna Tan, Hui Yin, Hongsheng Lin, Mingfen Li (2026) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-13157854.txt.

Description

Jiaqian He and co-authors published a study in 2026 on liver cancer drug resistance. A standard drug for advanced liver cancer often stops working. Low oxygen inside tumors seems to help that failure. The team probed one adapter protein that relays growth signals inside cells.

Data from cancer atlases showed the protein runs high in liver tumors and tracks with low-oxygen gene signs and poor survival. In cell tests, low oxygen blunted the drug's power to slow growth and kill cells. The drug under low oxygen raised the protein and a growth pathway it feeds. Blocking that pathway, or cutting the protein, restored the drug's bite and pushed cells to die. The authors name the protein a target to revive the drug's effect.

Catalog record

CREATORJiaqian He, Yinzhi Kong, Yunyong Wang, Qiaoling Fang, Hemeng Wu, Kewei Du, Yuzhen Luo, Jinna Tan, Hui Yin, Hongsheng Lin, Mingfen Li
YEAR2026
COLLECTIONPAPERS
FORMATTXT
FILE SIZE35 KB
VERSION1.0
LICENSECC BY 4.0
RIGHTSCC BY
SOURCEEurope PMC

Source: https://europepmc.org/articles/PMC13157854

Browse the full library · About the Tower of Babel